All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Join the Lymphoma Hub community
Stay up to date with the latest medical news in lymphoma & CLL by receiving trial data, therapy approvals, expert opinions, and more direct to your inbox. Sign up now!
Receive the latest updates in lymphoma & CLL
About the newsletter
The Lymphoma Hub newsletter provides healthcare professionals with up-to-date global advances in lymphoma & CLL relating to their classification, diagnosis, treatment, and management.
Each month our team research the latest unmet educational needs and produce evidence-based articles, videos, and podcasts that share new data, therapy approvals, expert opinions, and international congress coverage to enhance knowledge within the lymphoma & CLL community.